Orange Book product · Generic (ANDA)
RIFAMPIN
RIFAMPIN
At a glance
Sep 21, 2010
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 21, 2010
16 yr ago
Today
Pharmaceutical detail
Active ingredient
RIFAMPIN
Strength
600MG/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 065502
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RIFAMPIN
- 1989RIFADINBrand (NDA)
NDA 050627 · SANOFI AVENTIS US
- —RIFADINBrand (NDA)
NDA 050420 · SANOFI AVENTIS US
- —RIMACTANEBrand (NDA)
NDA 050429 · OXFORD PHARMS
- 2016RIFAMPINGeneric (ANDA)
ANDA 205039 · HIKMA PHARMS
- 2016RIFAMPINGeneric (ANDA)
ANDA 206736 · WATSON PHARMS TEVA
- 2014RIFAMPINGeneric (ANDA)
ANDA 091181 · FRESENIUS KABI USA
- 2014RIFAMPINGeneric (ANDA)
ANDA 204101 · AVET LIFESCIENCES
- 2013RIFAMPINGeneric (ANDA)
ANDA 090034 · LUPIN PHARMS
- 2008RIFAMPINGeneric (ANDA)
ANDA 065421 · MYLAN LABS LTD
- 2008RIFAMPINGeneric (ANDA)
ANDA 065390 · CHARTWELL MOLECULAR
- 2001RIFAMPINGeneric (ANDA)
ANDA 065028 · HIKMA
- 1999RIFAMPINGeneric (ANDA)
ANDA 064217 · HIKMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
